, 15 We evaluated the effect of SGLT2 inhibition on SBP in HFrEF patients, both with and without diabetes, and the efficacy and safety of dapagliflozin according to baseline SBP, in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).16–18. Here, SLC5A2 is linked to hydrops fetalis.